Randomized trial evaluates resmetirom's effect on liver fibrosis in patients with MASH, indicating potential benefits for metabolic disorders.
Introduction: MAESTRO-NASH is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH/MASH) and fibrosis. 966 patients with biopsy-confirmed NASH were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo administered once daily.
No takes yet. Share an insight, caveat, or question.
Jörn M. Schattenberg (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: